Why the study?
Do sulphonylureas increase cardiovascular risk in patients with type 2 diabetes?
Do sulphonylureas increase cardiovascular risk in patients with type 2 diabetes?
Despite theoretical concerns regarding ischaemic preconditioning, clinical evidence does not support differentiating sulphonylureas based on cardiovascular risk, emphasizing the primary goal of glycaemic control.
No takes yet. Share an insight, caveat, or question.
No support for differentiating sulphonylureas by ischaemic preconditioning; leaves open dedicated CVOTs beyond glycaemic control.
Valensi et al. (2006) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: